Bajaj HS, Burrows M, Blavignac J, et al. - In non‐alcoholic fatty liver disease, improvement in liver histology occurs with sustained weight loss. Researchers conducted this post‐hoc analysis of four phase 3, 56‐week, randomized, controlled trials examining the effects of extended‐release naltrexone and bupropion (NB) on alanine aminotransferase (ALT) and Fibrosis Index (FIB‐4) in adults with overweight or obesity. At baseline, 2,073 individuals (NB = 1310; placebo = 763; 79.0% female; 81.6% Caucasian) had mean: weight 101 kg, BMI 36.2 kg/m², ALT 26.9 IU/L, and FIB‐4 0.79. At 56 weeks, higher weight loss was noted in NB‐treated individuals relative to placebo (8.7 kg vs 3.2 kg). Improvement in ALT and FIB‐4 was observed in correlation with weight loss, independent of treatment. Overall findings suggest a possible correlation of NB‐associated weight loss with improvement in liver health as it normalizes ALT values for those with high baseline levels.